Seven Eight Capital’s Charles River Laboratories CRL Stock Holding History

Seven Eight Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,555	Closed	-$1.61M	–	500
2019 Q4	$1.61M	Buy	+10,555	New	+$1.46M	0.09%	351
2017 Q4	–	Sell	-2,900	Closed	-$313K	–	475
2017 Q3	$313K	Sell	2,900 -2,600	-47%	-$267K	0.04%	380
2017 Q2	$556K	Sell	5,500 -5,100	-48%	-$469K	0.08%	293
2017 Q1	$953K	Buy	10,600 +10,400	+5,200%	+$883K	0.18%	181
2016 Q4	$15K	Buy	+200	New	+$15.2K	﹤0.01%	543
2016 Q1	–	Sell	-1,000	Closed	-$80K	–	565
2015 Q4	$80K	Buy	+1,000	New	+$72.1K	0.05%	388
2015 Q2	–	Sell	-200	Closed	-$16K	–	551
2015 Q1	$16K	Buy	+200	New	+$14.8K	0.03%	363
2014 Q4	–	Sell	-300	Closed	-$17.9K	–	523
2014 Q3	$17.9K	Buy	300 +200	+200%	+$11.4K	0.01%	459
2014 Q2	$5K	Buy	+100	New	+$5.49K	﹤0.01%	481

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Seven Eight Capital's CRL Position: Q1 2020 in Review

Seven Eight Capital sold out of Charles River Laboratories (CRL) in Q1 2020, closing a stake of 10,555 shares — an estimated $1.61M sold.

Seven Eight Capital first reported a position in CRL in Q2 2014 and held it in 9 quarters. The position peaked at $1.61M in Q4 2019. 414 funds tracked by Wall St. Rank hold CRL as of Q1 2020.

Seven Eight Capital reported no remaining Charles River Laboratories position as of Q1 2020 after selling out during the quarter.
Seven Eight Capital sold 10,555 Charles River Laboratories shares in Q1 2020, an estimated $1.61M.
Seven Eight Capital first reported a position in Charles River Laboratories in Q2 2014 and held it in 9 quarters.
Seven Eight Capital's Charles River Laboratories position peaked at $1.61M in Q4 2019.
414 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2020.

Based on Seven Eight Capital's 13F filing for Q1 2020, filed 14 May 2020.